To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC48002 | DS45500853 |
DS45500853 is an estrogen-related receptor α (ERRα) agonist. DS45500853 inhibits the binding between receptor-interacting protein 140 (RIP140) corepressor peptide (10 nM) and GST-ERRα ligand-binding domain (LBD; 1.2 μM) with an IC50 value of 0.80 μM. DS45500853 can be used for the research of metabolic disorders, including type 2 diabetes mellitus (T2DM).
More description
|
|
| DC48001 | DS96432529 |
DS96432529 is a potent and orally active bone anabolic agent through CDK8 inhibition.
More description
|
|
| DC48000 | Dxd-d5 |
Dxd-D5 (Exatecan-D5 derivative for ADC) is a deuterium labeled Dxd. Dxd is a potent DNA topoisomerase I inhibitor, with an IC50 of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a) .
More description
|
|
| DC47999 | D-Xylofuranose, 1,2,3,5-tetraacetate |
D-Xylofuranose, 1,2,3,5-tetraacetate is the raw material for nucleotides synthesis.
More description
|
|
| DC47998 | Elomotecan hydrochloride |
Elomotecan (hydrochloride) is a potent inhibitor of topoisomerases I and II. Elomotecan (hydrochloride) is a camptothecin analog belonging to the homocamptothecin family (hCPT). Elomotecan (hydrochloride) reduces the proliferation of different tumor cells with higher potency than other anticancer drugs of reference targeting topoisomerases I or II.
More description
|
|
| DC47997 | ELOVL1-IN-1 |
ELOVL1-IN-1 is an ELOVL1 inhibitor extracted from patent WO2018107056A1, compound 87. ELOVL1-IN-1 can reduce very long chain fatty acid levels. ELOVL1-IN-1 can be used for the research of adrenoleukodystrophy (ALD).
More description
|
|
| DC47996 | Enzalutamide-d6 |
Enzalutamide D3 is a deuterium labeled Enzalutamide (MDV3100). Enzalutamide is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells.
More description
|
|
| DC47995 | ETP-45658 |
ETP-45658 is a potent PI3K inhibitor, with IC50s of 22.0 nM, 39.8 nM, 129.0 nM and 717.3 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. ETP-45658 also can inhibit DNA-PK (IC50=70.6 nM) and mTOR (IC50=152.0 nM). ETP-45658 can be used for the research of cancer.
More description
|
|
| DC47994 | Eubananin |
Eubananin is an effective inhibitor of the ATPase activity of the SARS Coronavirus helicase with an IC50 value of 2.8 μM.
More description
|
|
| DC47993 | FGN849 |
FGN849 is the catabolite of DGN549-L ADCs.
More description
|
|
| DC47992 | Flurocitabine |
Flurocitabine is a fluorinated anlydride analog of cytosine arabinoside, partially hydrolysecl in vivo into two active antitumor substances (arabinosyl-tluorocytosine (ara-FC) and arabinosyl-fluorouracil (ara-FU)). Flurocitabine has antitumor activity during phase I studies in acute leukemia and solid tumors.
More description
|
|
| DC47991 | Fmoc-Tyr(3-F,tBu)-OH |
Fmoc-Tyr(3-F,tBu)-OH is a cyclic peptide compound with high membrane permeability and can specifically binds to a target molecule (extracted from patent WO2018225864A1).
More description
|
|
| DC47988 | Fulvic Acid |
Fulvic Acid is a natural healthy product, which comes from humic substances produced by microorganisms in soil. Fulvic Acid can modulate the immune system, influence the oxidative state of cells, and improve gastrointestinal function. Fulvic Acid has the potential for the treatment of chronic inflammatory diseases, including diabetes.
More description
|
|
| DC47987 | FXR/TGR5 agonist 1 |
FXR/TGR5 agonist 1 has agonist action on FXR and TGR5, and can be used for the treatment of fatty liver disease.
More description
|
|
| DC47986 | Gemcitabine elaidate hydrochloride |
Gemcitabine elaidate (CP-4126) hydrochloride is lipophilic pro-drug of Gemcitabine. Gemcitabine elaidate hydrochloride is converted to Gemcitabine by esterases in order to be phosphorylated. Gemcitabine elaidate hydrochloride exhibits anti-tumor activity.
More description
|
|
| DC47984 | GRK-IN-1 |
GRK-IN-1 is a potential G protein-coupled receptor kinase (GRK) inhibitor.
More description
|
|
| DC47983 | GSK852 |
GSK852 is a highly potent, second bromodomain (BD2)-selective, bromo and extra-terminal domain (BET) inhibitor (pIC50 = 7.9).
More description
|
|
| DC47982 | GW 610 |
GW 610 (NSC 721648), an antitumor agent, shows potent and selective anticancer activity against lung, colon, and breast cancer cell lines.
More description
|
|
| DC47981 | hFSH-β-(33-53) (TFA) |
hFSH-β-(33-53) TFA, a thiol-containing peptide which corresponds to a second FSH receptor-binding domain, is a FSHR (follicle-stimulating hormone receptor) antagonist. hFSH-β-(33-53) TFA inhibits binding of FSH to receptor and is a partial agonist of estradiol synthesis in Sertoli cells.
More description
|
|
| DC47979 | HNMPA |
HNMPA is a membrane impermeable insulin receptor tyrosine kinase inhibitor. HNMPA inhibits serine and tyrosine autophosphorylation by the human insulin receptor. HNMPA has no effect on protein kinase C or cyclic AMP-dependent protein kinase activities
More description
|
|
| DC47978 | Homocarnosine |
Homocarnosine is a dipeptide of γ-aminobutyric acid (GABA) and histidine unique to brain. Homocarnosine is an inhibitory neuromodulator synthesized in the neuron from GABA and exhibiting anticonvulsant effects.Homocarnosine has antioxidant and anti-inflammatory actions, prevention of DNA damage, and inhibition of advanced glycation end-product formation.
More description
|
|
| DC47976 | Ibiglustat succinate |
Ibiglustat (Venglustat) succinate is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat succinate can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease.
More description
|
|
| DC47975 | IBS008738 |
IBS008738 is a potent TAZ activator. IBS008738 stabilizes TAZ, increases the unphosphorylated TAZ level, enhances the association of MyoD with the myogenin promoter, upregulates MyoD-dependent gene transcription, and competes with myostatin in C2C12 cells. IBS008738 enhances myogenesis in C2C12 cells and facilitates muscle repair in a muscle injury model.
More description
|
|
| DC47974 | IL-17A modulator-1 |
IL-17A modulator-1 is a IL-17A modulator, extracted from patent WO2021239743+A1, example 9. IL-17A modulator-1 inhibits the biological action of IL-17A with a pIC50 of 8.2. IL-17A modulator-1 can be used for the research of diseases or disorders associated with modulation of IL-17A activity including diseases with an immune component or autoimmune pathol, cancer and neurodegenerative disorders.
More description
|
|
| DC47973 | IL-17A modulator-2 |
IL-17A modulator-2 is a IL-17A modulator, extracted from patent WO2021239743+A1, example 27. IL-17A modulator-2 inhibits the biological action of IL-17A with a pIC50 of 8.3. IL-17A modulator-2 can be used for the research of diseases or disorders associated with modulation of IL-17A activity including diseases with an immune component or autoimmune pathol, cancer and neurodegenerative disorders.
More description
|
|
| DC47972 | INCA-6 |
INCA-6 (Triptycene-1,4-quinone) is a cell-permeable NFAT inhibitor. INCA-6 specifically blocks targeting of NFAT(P) substrate to the calcineurin (CN) phosphatase site and is an effective inhibitor of CN-NFAT signaling.
More description
|
|
| DC47971 | Inonophenol C |
Inonophenol C is a neurotrophic and protective agent against neurodegenerative disorders.
More description
|
|
| DC47970 | Iodobananin |
Iodobananin is an effective inhibitor of the ATPase activity of the SARS Coronavirus helicase with an IC50 value of 0.54 μM.
More description
|
|
| DC47968 | JNJ-DGAT2-A |
JNJ-DGAT2-A is a selective diacylglycerol acyltransferase 2 (DGAT2) inhibitor with an IC50 value of 0.14 μM in human DGAT2-expressing Sf9 insect cell membranes. JNJ-DGAT2-A can be used for the research of triglyceride (TG) synthesis.
More description
|
|
| DC47967 | KCNQ2/3 activator-1 |
KCNQ2/3 activator-1 is an activator of Kv7.2/Kv7.3 (KCNQ2/3) potassium channel. KCNQ2/3 activator-1 has the potential in relieving pain (the main problem from medical treatment) (extracted from patent WO2021113757A1, compound A).
More description
|
|